LIXTE Biotechnology Expands Cancer Treatment Pipeline with LiGHT Proton Therapy Acquisition

LIXTE Biotechnology Holdings has expanded its cancer treatment pipeline through the acquisition of Liora Technologies, a company pioneering proton therapy systems for treating various cancers. The acquisition includes Liora's proprietary LiGHT System, which offers significant advantages over existing proton therapy technologies. This strategic move positions LIXTE to address critical limitations in current cancer treatment approaches while potentially improving patient outcomes and accessibility.

The LiGHT System represents a technological breakthrough in proton therapy, providing a highly adaptable proton beam capable of delivering very high dose rates to deep-seated tumors. According to Professor Steve Myers, former Director of Accelerators and Technology at CERN, the system offers unique biological effects while substantially reducing installation costs and treatment sessions compared to current technologies. This efficiency improvement is expected to significantly increase the number of patients that treatment centers can serve, addressing a major barrier to proton therapy accessibility.

This acquisition complements LIXTE's existing cancer therapy development efforts, which include their first-in-class lead clinical PP2A inhibitor, LB-100. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at www.lixte.com, LB-100 has shown potential to significantly enhance chemotherapies and immunotherapies, potentially improving outcomes for cancer patients. LIXTE's approach represents a pioneering effort in activation lethality, an entirely new field of cancer biology that is advancing a new treatment paradigm supported by a comprehensive patent portfolio.

The integration of LiGHT technology into LIXTE's pipeline creates synergistic opportunities for cancer treatment innovation. Proton therapy's precision targeting combined with LIXTE's pharmaceutical developments could lead to more effective combination therapies. Current proof-of-concept clinical trials for ovarian clear cell carcinoma and metastatic colon cancer demonstrate the company's commitment to advancing multiple treatment modalities. The acquisition's importance extends beyond technological advancement to address practical healthcare challenges, potentially making advanced cancer treatments more accessible and affordable while improving treatment efficiency and patient throughput at medical facilities.